Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

  • Irene Homminga
  • Rob Pieters
  • Anton W Langerak
  • de Rooi
  • J Johan
  • Andrew Stubbs
  • Monique Verstegen
  • Maartje Vuerhard
  • Jessica Buijs-Gladdines
  • Clarissa Kooi
  • Petra Klous
  • Pieter van Vlierberghe
  • Adolfo A Ferrando
  • Jean Michel Cayuela
  • Brenda Verhaaf
  • Martin Horstmann
  • Martin Horstmann
  • Valerie de Haas
  • Anna-Sophia Wiekmeijer
  • Karin Pike-Overzet
  • Frank J T Staal
  • Wouter de Laat
  • Jean Soulier
  • Francois Sigaux
  • Jules P P Meijerink

Abstract

To identify oncogenic pathways in T cell acute lymphoblastic leukemia (T-ALL), we combined expression profiling of 117 pediatric patient samples and detailed molecular-cytogenetic analyses including the Chromosome Conformation Capture on Chip (4C) method. Two T-ALL subtypes were identified that lacked rearrangements of known oncogenes. One subtype associated with cortical arrest, expression of cell cycle genes, and ectopic NKX2-1 or NKX2-2 expression for which rearrangements were identified. The second subtype associated with immature T cell development and high expression of the MEF2C transcription factor as consequence of rearrangements of MEF2C, transcription factors that target MEF2C, or MEF2C-associated cofactors. We propose NKX2-1, NKX2-2, and MEF2C as T-ALL oncogenes that are activated by various rearrangements.

Bibliographical data

Original languageEnglish
Article number4
ISSN1535-6108
Publication statusPublished - 2011
pubmed 21481790